Catalyst Pharmaceuticals reported strong revenue growth and cash position, driven by impressive performance in their key products FIRDAPSE and AGAMREE. However, challenges such as FYCOMPA's revenue decline due to generic competition and increased SG&A expenses were noted. Overall, the highlights of strong growth and strategic advancements significantly outweigh these challenges.

Company Guidance -

Q3 2025

During the Catalyst Pharmaceuticals Q2 2025 financial results call, the company's leadership provided comprehensive guidance on various metrics. Total revenue for Q2 2025 reached $146.6 million, marking a year-over-year increase of 19.4%. The first half of 2025 saw total revenue grow by 30.2% to $288 million. The company ended the quarter with a cash position of $652.8 million. Catalyst reaffirmed its full-year 2025 revenue guidance of $545 million to $565 million, with specific guidance for FIRDAPSE set at $355 million to $360 million, AGAMREE between $100 million and $110 million, and FYCOMPA at $90 million to $95 million. FIRDAPSE achieved $84.8 million in Q2 net product revenue, growing 16.9% in the first half of 2025 compared to the same period in 2024. AGAMREE generated $27.4 million in Q2 revenue, a 213% year-over-year increase, driven by a 90% patient retention rate. FYCOMPA's Q2 revenue was $34.3 million, despite a 6% year-over-year decline due to anticipated generic competition. The company reported a GAAP net income of $52.1 million, a 27.7% increase from Q2 2024. Non-GAAP net income was $86.4 million, equating to $0.68 per diluted share. Catalyst's strategy focuses on expanding FIRDAPSE's market presence, particularly in the oncology segment, and sustaining AGAMREE's adoption as a leading treatment for Duchenne Muscular Dystrophy.

Record-Setting Revenue Growth

Total revenue for Q2 2025 reached $146.6 million, a 19.4% increase year-over-year. Year-to-date, total revenue grew 30.2% to $288 million.

Strong Performance of FIRDAPSE

FIRDAPSE generated net product revenue of $84.8 million in Q2 2025, a growth of $7.5 million versus Q2 2024. Year-to-date revenue is $168.6 million, up 16.9% over the first half of 2024.

AGAMREE's Impressive Growth

AGAMREE achieved $27.4 million in net product revenue in Q2 2025, a 213% increase year-over-year. First half net revenues reached $49.4 million, up 398% from the prior year.

Strong Cash Position

Catalyst ended the second quarter with a cash position of $652.8 million, an increase of $135.2 million from December 31, 2024.

New Leadership and Expansion Strategy

Dr. Will Andrews joined as Chief Medical Officer, and Dr. Dan Curran joined the Board of Directors, enhancing leadership in rare diseases.

Catalyst Pharma (CPRX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CPRX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.33 / -	0.35	―	―	―
Aug 06, 2025	2025 (Q2)	0.39 / 0.41	0.33	24.24% (+0.08)	―
May 07, 2025	2025 (Q1)	0.34 / 0.45	0.19	136.84% (+0.26)	―
Feb 26, 2025	2024 (Q4)	0.34 / 0.44	0.31	41.94% (+0.13)	―
Nov 06, 2024	2024 (Q3)	0.30 / 0.35	-0.29	220.69% (+0.64)	―
Aug 07, 2024	2024 (Q2)	0.23 / 0.33	0.33	0.00% (0.00)	―
May 08, 2024	2024 (Q1)	0.20 / 0.19	0.26	-26.92% (-0.07)	―
Feb 28, 2024	2023 (Q4)	0.27 / 0.31	0.22	40.91% (+0.09)	―
Nov 08, 2023	2023 (Q3)	-0.30 / -0.29	0.2	-245.00% (-0.49)	―
Aug 09, 2023	2023 (Q2)	0.25 / 0.33	0.2	65.00% (+0.13)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CPRX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$21.79	$19.64	-9.87%
May 07, 2025	$23.46	$22.76	-2.98%
Feb 26, 2025	$20.58	$21.66	+5.25%
Nov 06, 2024	$22.71	$23.25	+2.38%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Catalyst Pharma (CPRX) report earnings?

Catalyst Pharma (CPRX) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Catalyst Pharma (CPRX) earnings time?

Catalyst Pharma (CPRX) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CPRX EPS forecast?

CPRX EPS forecast for the fiscal quarter 2025 (Q3) is 0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing